These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 8787551)
1. Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Drake JC; Allegra CJ; Moran RG; Johnston PG Biochem Pharmacol; 1996 May; 51(10):1349-55. PubMed ID: 8787551 [TBL] [Abstract][Full Text] [Related]
2. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518 [TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540 [TBL] [Abstract][Full Text] [Related]
6. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells. Dolnick BJ; Lu K; Yin MB; Rustum YM Adv Enzyme Regul; 1997; 37():95-109. PubMed ID: 9381988 [TBL] [Abstract][Full Text] [Related]
8. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours. Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Wang W; McLeod HL; Cassidy J; Collie-Duguid ES Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966 [TBL] [Abstract][Full Text] [Related]
10. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Aherne GW; Hardcastle A; Raynaud F; Jackman AL Biochem Pharmacol; 1996 May; 51(10):1293-301. PubMed ID: 8787544 [TBL] [Abstract][Full Text] [Related]
12. Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs. Takemura Y; Kobayashi H; Miyachi H; Gibson W; Kimbell R; Jackman AL Jpn J Cancer Res; 1996 Jul; 87(7):773-80. PubMed ID: 8698629 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor. Kobayashi H; Takemura Y; Miyachi H Cancer Chemother Pharmacol; 1998; 42(2):105-10. PubMed ID: 9654109 [TBL] [Abstract][Full Text] [Related]
14. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells. Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962 [TBL] [Abstract][Full Text] [Related]
15. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Backus HH; Pinedo HM; Wouters D; Padrón JM; Molders N; van Der Wilt CL; van Groeningen CJ; Jansen G; Peters GJ Int J Cancer; 2000 Sep; 87(6):771-8. PubMed ID: 10956384 [TBL] [Abstract][Full Text] [Related]
16. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465 [TBL] [Abstract][Full Text] [Related]
17. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558 [TBL] [Abstract][Full Text] [Related]
18. Influence of resistance to 5-fluorouracil and tomudex on [18F]‑FDG incorporation, glucose transport and hexokinase activity. Law AA; Collie-Duguid ES; Smith TA Int J Oncol; 2012 Jul; 41(1):378-82. PubMed ID: 22576694 [TBL] [Abstract][Full Text] [Related]
19. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Schultz RM; Patel VF; Worzalla JF; Shih C Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579 [TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Song B; Wang Y; Titmus MA; Botchkina G; Formentini A; Kornmann M; Ju J Mol Cancer; 2010 Apr; 9():96. PubMed ID: 20433742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]